Designing the Best Partner in Crime for Cancer Therapy

Time: 1:30 pm
day: Day One


  • Introducing an oncolytic virus engineered to enhance replication and heat up the tumor microenvironment can overcome challenges facing cancer immunotherapeutics
  • The choice of transgenes for the oncolytic virus should depend on the combination agent to demonstrate synergy and potentiate overall therapeutic effect
  • HSV-1’s high payload capacity allows testing for different combination strategies within a single system, pushing the boundaries to explore monotherapy potential